Prevalence and risk factors of disability and anxiety in a retrospective cohort of 432 survivors of Coronavirus Disease-2019 (Covid-19) from China

Siyi Zhu[1,2,¶]; Qiang Gao[1,2,¶]; Lin Yang [1,2,¶]; Yonghong Yang[1,2,¶]; Wenguang Xia[4]; Xiguo Cai[5]; Yanping Hui[6]; Di Zhu[7]; Yanyan Zhang[8]; Guiqing Zhang[9]; Shuang Wu[10]; Yiliang Wang[11]; Zhiqiang Zhou[12]; Hongfei Liu[13]; Changjie Zhang[14]; Bo Zhang[15]; Jianrong Yang[16]; Mei Feng[3]; Zhong Ni[3]; Baoyu Chen[1]; Chunping Du[1,2]; Hongchen He[1,2]; Yun Qu[1,2]; Quan Wei[1,2]; Chengqi He[1,2,17,¶*]; Jan D. Reinhardt[17,18,19,20,¶*].

[1] Rehabilitation Medical Center, West China Hospital, Sichuan University, Chengdu, China.

[2] Rehabilitation Medicine Key Laboratory of Sichuan Province, Sichuan University, Chengdu, China.

[3] Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.

[4] Hubei Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan, Hubei, China.

[5] Henan Provincial People's Hospital, Zhengzhou, Henan, China.

[6] The Second Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xian, Shanxi, China.

[7] Zhejiang provincial People's Hospital, Hangzhou, Zhejiang, China.

[8] Qilu Hospital of Shandong University, Jinan, Shandong, China.

[9] The First Affiliated Hospital, School of Medicine, Shihezi University, Xinjiang, China.

[10] The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.

[11] Chongqing Three Gorges Central Hospital, Chongqing, China.

[12] Inner Mongolia Autonomous Region Baotou Central Hospital, Baotou, China.

[13] General Hospital of General Bureau of Agricultural Reclamation of Heilongjiang

Province, Harbin, China.

[14] The Second Xiangya Hospital of Central South University, Changsha, China.

[15] Nanchong central hospital, Nanchong, Sichuan, China.

[16] Garze People's Hospital, Garze Tibetan Autonomous Prefecture, Sichuan, China.

[17] Institute for Disaster Management and Reconstruction of Sichuan University and

Hong Kong Polytechnic University, Sichuan University, Chengdu, China.

[18] Swiss Paraplegic Research, Switzerland.

[19] Department of Health Sciences and Medicine, University of Lucerne, Switzerland.

[20] Committee for Rehabilitation Disaster Relief, International Society for Physical and

Rehabilitation Medicine, Geneva, Switzerland.

¶S Zhu, Q Gao, L Yang, Y Yang, Q Wang, C He and JD Reinhardt contributed equally

and share first authorship.

*Correspondence to: Prof Chengqi He MD, Rehabilitation Medical Center, West China

Hospital, No.37 Guoxue Alley, Wuhou District, Chengdu, China **hxkfhcq@126.com**

or Prof Jan D. Reinhardt PhD, Institute for Disaster Management and Reconstruction of

Sichuan University and Hong Kong Polytechnic University, Sichuan University, 122

Huanghe Zhong Lu, Chengdu 610041, Sichuan, China **jan.reinhardt@paraplegie.ch**.

Abstract

Objective: To estimate the prevalence of disability and anxiety in Covid-19 survivors at

discharge from hospital and analyze relative risk by exposures.

Design: Multi-center retrospective cohort study.

Setting: Twenty-eight hospitals located in eight provinces of China.

Methods: A total of 432 survivors with laboratory-confirmed SARS CoV-2 infection

participated in this study. At discharge, we assessed instrumental activities of daily living

(IADL) with Lawton's IADL scale, dependence in activities of daily living (ADL) with the

Barthel Index, and anxiety with Zung's self-reported anxiety scale. Exposures included

comorbidity, smoking, setting (Hubei vs. others), disease severity, symptoms, and length

of hospital stay. Other risk factors considered were age, gender, and ethnicity (Han vs.

Tibetan).

Results: Prevalence of at least one IADL problem was 36.81% (95% CI: 32.39-41.46).

ADL dependence was present in 16.44% (95% CI: 13.23-20.23) and 28.70% (95% CI:

24.63- 33.15) were screened positive for clinical anxiety. Adjusted risk ratio (RR) of IADL

limitations (RR 2.48, 95% CI: 1.80-3.40), ADL dependence (RR 2.07, 95% CI 1.15-3.76),

and probable clinical anxiety (RR 2.53, 95% CI 1.69-3.79) were consistently elevated in

survivors with severe Covid-19. Age was an additional independent risk factor for IADL

limitations and ADL dependence; and setting (Hubei) for IADL limitations and anxiety.

Tibetan ethnicity was a protective factor for anxiety but a risk factor for IADL limitations.

Conclusion: A significant proportion of Covid-19 survivors had disability and anxiety at

discharge from hospital. Health systems need to be prepared for an additional burden

resulting from rehabilitation needs of Covid-19 survivors.

Keywords: COVID-19; Rehabilitation; Disability; Activities of Daily Living; Mental Health;

Anxiety.

Introduction

With rapidly increasing numbers of confirmed cases and deaths caused by the

Coronavirus Disease-2019 (Covid-19) pandemic, clinical outcomes research has almost

exclusively focused on disease progression and mortality[1]. With the case fatality rate

estimated to lie somewhere between 0.56 and 9.38 percent globally (95% prediction

interval, I^2 = 100%),[2] it is obvious however that a vast majority of people actually

survive Covid-19. A substantial proportion of survivors have experienced severe disease

episodes requiring hospitalization and - in a considerable number of cases - intensive

care including mechanical ventilation[3]. In addition, contracting a potentially fatal

disease is stressful and can cause anxiety and other psychiatric manifestations in many

patients.[4] It would be naïve to assume that health problems just disappear upon

discharge from acute care or when viral RNA is no longer detectable, and equally naïve

to take planned and systematic follow up of patients for granted.[5, 6] Yet, the burden of

disease resulting from physical and psychological sequelae of Covid-19 in patients

surviving the disease as well as potential long-term adverse effects from treatments

including steroids such as Dexamethasone are just beginning to catch attention[7, 8].

Globally, respiratory infections and tuberculosis assume already the fourth rank of all

diseases in terms of disability adjusted life years (DALYs) and the 17th rank in years

lived with disability (YLD). In infectious disease, they sadly rank first and second,

respectively.[9, 10] Covid-19 will increase this burden considerably and cause longer

term mental and physical health problems, work disability, and reduced quality of life in

survivors, frontline health professionals, and those quarantined.[11, 12] What we know

from the 2002/2003 Severe Acute Respiratory Syndrome (SARS) epidemic is not

encouraging. In Hong Kong for example, about 80 percent of SARS survivors still

needed follow-up treatment two years after the outbreak had been contained.[13]

The number of patients needing follow-up care and rehabilitation due to Covid-19 will be

unprecedented. Countries need to consider and plan for this additional long-term

challenge to the health system. It is important to understand risk factors for disability and

mental health problems now in order to direct scarce resources and meet windows of

opportunity for treatment. This study makes a first attempt to address this issue. We

aimed to (1) estimate the prevalence of disability and anxiety in Covid-19 survivors from

eight Provinces/centrally governed municipalities of the PR China at discharge from

acute inpatient treatment, and (2) investigate relative risk of adverse outcomes by

various determinants including gender, age, comorbidity, setting, ethnicity and disease

severity. Prevalence estimates are important to gain insight in the potential number of

patients needing follow-up care. Analyzing risk factors is instrumental in identifying

vulnerable groups and allocating resources for early interventions.

Methods

Study design

We conducted a multi-center retrospective cohort study. The study protocol was approved by the ethics committee of West China Hospital, Sichuan University (2020-273).

Subjects

Four hundred and thirty-two Covid-19 survivors were surveyed who had received treatment in 28 designated hospitals in Hubei, Sichuan, Guizhou, Henan, Neimenggu (inner Mongolia), Shandong, Hainan, and Chongqing from January 18 to March 15, 2020 and gave informed consent. Included were adults (≥ 16 years) who had laboratory-confirmed SARS coronavirus-2 (SARS CoV-2) infection and met the diagnostic criteria of the Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7) issued by the National Health Commission of the PR China (Third edition).[14] Survivors further needed to be in stable medical condition and have been discharged or be about to be discharged from the participating centers. Excluded were patients with pneumonia caused by other types of coronaviruses, seasonal influenza, bacteria, or other not SARS CoV-2 etiology.

Patients were contacted by health professionals who were in charge of their treatment. All health professionals were instructed on implementation of the study protocol, informed consent procedures, and possible sources of bias by videoconference.

Measures

Outcomes: Outcomes were disability and anxiety. Cut off date for outcome assessment was April 7, 2020. Disability was measured in two ways: (1) Limitations in instrumental activities of daily living (IADL) were assessed with the Lawton IADL scale[15] and

classified into no limitations vs. one or more limitations (primary outcome). An index of

the number of reported IADL limitations was also created. (2) Dependence in activities of

daily living (ADL) was measured with the Barthel Index[16] and classified into severe or

moderate dependence vs. mild dependence/independence.[17] Anxiety was evaluated

with Zung's Self-Reported Anxiety Scale[18] (SAS) and classified into probable clinical

anxiety disorder vs. not according to a conservative cutoff recommended for

research.[19] Outcome data were patient-reported and collected with an online

questionnaire.

Risk factors: Clinical and demographic data were extracted from hospital records by

participating health professionals. Current smoking status was self-reported by

participants. Demographic data included age, gender, province (Hubei vs. others), and

ethnicity (Han vs. Tibetan). Having received treatment in Hubei was considered a risk

factor because of the particular situation in Hubei which was the epicenter of the

epidemic in China representing about 80 percent of confirmed cases. Ethnicity was

included as a significant proportion of the sample from Sichuan was from the Tibetan

ethnic group, and belonging to a minority ethnic group is known to be associated with

health outcomes in other disease. Clinical data included comorbidity, disease severity,

symptoms at admission, scope of pneumonia, and length of inpatient stay. Recorded

comorbid conditions included COPD, chronic bronchitis, pulmonary fibrosis,

hypertension, diabetes, cardiovascular disease, kidney disease, hepatitis, rheumatism,

and gout. Degree of Covid-19 severity was classified according to the Chinese

standard.[14] Patients were defined as severe cases when they met one of the following

criteria at any time during hospitalization: acute respiratory distress, respiratory rate ≥30

breath/min; pulse oxygen saturation (SpO2) ≤93% at rest; arterial blood partial pressure

of oxygen/fraction of inspired oxygen (PaO2/FiO2) ≤300 mmHg (1 mmHg = 0.133 kPa);

respiratory failure requiring mechanical ventilation; septic shock; failure of other organs

requiring ICU treatment. Symptoms recorded at admission included fever, cough,

diarrhea, fatigue and pain. Scope of pneumonia was noted as uni- or bilateral per

radiographic findings. Data on length of hospital stay were available for 408 patients

(94.44%).

Sample size calculation

Sample size to detect a two-fold relative risk for reporting one or more IADL limitations in

the severe disease group as compared to the non-severe group with a power of 80%

and alpha error of 5% was estimated under the following assumptions: 0.2 ratio of

severe to non severe group (based on patients received at our own center), 15 percent

prevalence of outcome in non-severe group. This yielded a minimal sample size of 401

(67 severe, 334 non-severe).

Analysis

Prevalence of limitations in IADL, ADL dependence, and anxiety for the full sample and

by disease severity were provided with 95% confidence intervals (CIs) estimated from

logistic regression. Risk ratios (RR) and 95% CIs for gender, age group (<= 50, 50-60, >

60 years), province (others vs. Hubei), ethnicity (Han vs. Tibetan), comorbid health

conditions (none, one, multiple), disease severity (non-severe vs. severe), symptoms

(<=1, >1) at admission, and infection scope (unilateral vs. bilateral) were estimated with

log-linear Poisson regression with robust standard errors.[20] Since longer time of being

hospitalized could increase anxiety, length of hospital stay was included in the anxiety-

model in addition. For each outcome unadjusted RR and RR adjusted for all other

potential risk factors evaluated were provided. Zero-inflated Poisson (ZIP) regression

was used to estimate the effect of risk factors on the extent of IADL limitations. ZIP

regression assumes that there are two groups in the population from which the data are

sampled, one which always has zero counts, and one which may have zero or higher

counts. Young people with non-severe disease who have no comorbidity may never

develop IADL limitations, while other groups may develop (additional) IADL limitations

due to factors associated with disease progression. ZIP regression simultaneously

performs logistic and Poisson regression making two types of predictions: (1) prediction

of excess zeros assuming a binary dependent variable (no IADL limitations vs. one or

more), (2) prediction of the count portion (number of experienced IADL limitations).

Predictors included in the logistic part were the following background factors: age group

and interaction of age and disease severity, province, ethnicity, smoking, and comorbid

conditions. Predictors included in the count part were potential drivers of disease

consequences: disease severity, interaction of age and disease severity, symptoms, and

infection scope. Vuong's test confirmed fit of the ZIP model.

All analyses were performed with Stata 14 (Stata corporation, Texas, USA).

Results

Demographic and clinical characteristics and prevalence of outcomes of the study

participants are provided in Table 1. Median age was 49 (IQR 35-60) and 49% were

female. About one third of the study participants were classified as severe cases. Fever,

cough, and fatigue were the most common symptoms at admission. A majority had no

pre-existing health condition and were non-smokers. Patients with severe Covid-19 were

older, were more often from Hubei and belonged to the Han majority, presented with

more symptoms, had more often bilateral pneumonia, and stayed in the hospital for a

longer time. More pre-existing health conditions were present in severe cases, but the

percentage of smokers was lower. Over one third of Covid-19 survivors had at least one

IADL limitation, about 15 percent had at least moderate ADL dependence, and six

percent were severely dependent. Probable clinical anxiety disorder was found in about

29 percent of the population. Prevalence of all outcomes was more than four times

higher in survivors of severe Covid-19 than in those with non-severe disease.

Table 1. Demographic and Clinical Characteristics of study participants (I) and prevalence of outcomes (II)

I. Demographic and clinical characteristics	All participants (N=432)	By disease severity	
		non-severe (n=285, 65.97%)	severe (n=147, 34.03%)
Female sex – no./total no. (%)	207/432 (47.92)	138/285 (48.42)	69/147 (46.94)
Age			
Median (IQR) in years	49 (35-60)	45 (32.5-54.5)	57 (47-68)
Distribution – no./total no. (%)			
< 50	218/431 (50.58)	173/284 (60.92)	45/147 (30.61)
50-60	108/431 (25.06)	69/284 (24.30)	39/147 (26.53)
> 60	105/431 (24.36)	42/284 (14.79)	63/147 (42.86)
Province – no./total no. (%)			
Hubei	169/432 (39.12)	73/285 (25.61)	96/147 (65.31)
Sichuan	162/432 (37.50)	144/285 (50.53)	18/147 (12.24)
Chongqing	38/432 (8.80)	29/285 (10.18)	9/147 (6.12)
Henan	30/432 (6.94)	15/285 (5.26)	15/147 (10.20)
Guizhou	24/432 (5.56)	17/285 (5.96)	7/147 (4.76)
Other	9/432 (2.08)	7/285 (2.46)	2/147 (1.36)
Ethnicity – no./total no. (%)			

Han	360/432 (83.33)	220/285 (77.19)	140/147 (95.24)
Tibetan	72/432 (16.67)	65/285 (22.81)	7/147 (4.76)
Smoking history, yes – no./total no. (%)	62/432 (14.35)	46/285 (16.14)	16/147 (10.88)
Pre-existing comorbidity – no./total no. (%)			
none	300/432 (69.44)	226/285 (79.30)	74/147 (50.34)
one	79/432 (18.29)	37/285 (12.98)	42/147 (28.57)
multi	53/432 (12.27)	22/285 (7.72)	31/147 (21.09)
Symptoms on admission – no./total no. (%)			
Fever	249/432 (57.64)	125/285 (43.86)	124/147 (84.35)
Cough	257/432 (59.49)	139/285 (48.77)	118/147 (80.27)
Fatigue	153/432 (35.42)	70/285 (24.56)	83/147 (56.46)
Pain	68/432 (15.74)	40/285 (14.04)	28/147 (19.05)
Diarrhea	46/432 (10.65)	24/285 (8.42)	22/147 (14.97)
Bilateral infection scope[&] - no./total no. (%)	362/432 (83.80)	221/285 (77.54)	141/147 (95.92)
Length of hospital stay[§]			
Median (IQR) in days	18 (12-25)	15 (11-22)	23 (15.5-31.61)
Distribution – no./total no. (%)			
1-14 days	160/408 (39.22)	130/268 (48.51)	30/140 (21.43)
>14 days	248/408 (60.78)	138/268 (51.49)	110/140 (78.57)
Discharge Destination[§] - no./total no. (%)			
Discharged home	278/412 (67.48)	215/269 (79.93)	63/143 (44.06)
Discharged to 14-day quarantine	128/412 (31.07)	52/269 (19.33)	76/143 (53.15)
Referred to other hospital	6/412 (1.46)	2/269 (0.74)	4/143 (2.80)
Mechanical Ventilation– no./total no. (%)			
No	395/411 (96.11)	268/268 (100.00)	127/143 (88.81)

Yes	16/411 (3.89)	0/268 (0.00)	16/143 (11.19)
II. Outcomes*			
Disability, percent (95% CI)			
One or more IADL limitations	36.81 (32.39-41.46)	18.25 (14.18-23.16)	72.79 (65.04-79.37)
Moderate ADL dependence	16.44 (13.23-20.23)	6.32 (4.01-9.80)	36.05 (28.71-44.11)
Severe ADL dependence	5.56 (3.75-8.15)	2.46 (1.17-5.06)	11.56 (7.31-17.82)
Anxiety, percent (95% CI)	28.70 (24.63-33.15)	13.33 (9.86-17.80)	58.50 (50.38-66.19)

[§]Scope of pneumonia as confirmed by radiography. [&]For 24 (5.56%) patients discharge date had not been entered in the data form. *Confidence intervals estimated from logistic regression. CI = confidence interval. IADL = instrumental activities of daily living. ADL = activities of daily living.

Results on risk factors for disability and anxiety are displayed in Fig 1 and 2 (for detailed estimates see S1-3 Tables). Risk ratios for reporting at least one IADL limitation (Fig 1, upper panel) were increased in the older age groups, particularly in survivors aged older than 60 years, in patients from Hubei, and in survivors with severe Covid-19. The adjusted model also showed an elevated relative risk in survivors from the Tibetan ethnic group. Only in unadjusted models was the relative risk of having one or more IADL limitations clearly elevated in survivors with comorbidities, in patients with more symptoms at admission, and in those with bilateral infections. Both in unadjusted and adjusted models, the relative risk for ADL dependence (Fig 1 lower panel) was consistently increased in Covid-19 survivors aged older than 60 years, and in participants with severe disease course and more symptoms. All individual risk ratios

were higher in unadjusted models. Setting, comorbidity, and infection site played a role

in unadjusted analysis only.

Fig 1. Disability (IADL limitations and ADL dependence) in relation to potential risk

factors. Risk ratios and 95% confidence intervals. Estimated from log-linear Poisson

regression with robust standard errors; unadjusted risk ratios are estimated from

univariable model for the effect of the respective predictor on the outcome, adjusted risk

ratios are estimated from multivariable model containing all potential risk factors. IADL =

Instrumental Activities of Daily Living. ADL = Activities of Daily Living.CI=confidence

interval. Note: In the case of ADL dependence, the upper limit of the confidence interval

for the unadjusted estimate of age > 60 years has been truncated for better readability of

the other effects (see S1-3 Tables for details). Adjusted model and unadjusted model for

age have been estimated for 431 cases (because of one missing date of birth).

Fig 2. Probable clinical anxiety in relation to potential risk factors. Risk Ratios and

95% confidence intervals. Estimated from log-linear Poisson Regression with robust

standard errors; unadjusted risk ratios are estimated from univariable model for the

effect of the respective predictor on the outcome, adjusted risk ratios are estimated from

multivariable model containing all potential risk factors. The adjusted model has been

estimated for 407 cases (because of missing information regarding length of stay for 24

cases and one case with missing date of birth). [&]Unadjusted model estimated for 407

cases (because of missing information regarding length of stay for 24 cases and one

case with missing date of birth). CI=confidence interval.

Having severe Covid-19 was the strongest risk factor for probable clinically relevant

anxiety, followed by having received treatment in Hubei province (Fig 2). In turn,

belonging to the Tibetan group was associated with a largely decreased relative risk of

anxiety. There was a trend for an increased relative risk of anxiety in survivors who had

stayed in the hospital for more than 14 days. Older age, comorbidity, symptoms, and

scope of pneumonia played a role in unadjusted analysis only.

Table 2 show the results of the ZIP regression of the number of IADL limitations on risk

factors. Hospitalization in Hubei, Tibetan ethnicity, and multi-comorbidity were

associated with lower odds of having a zero count of IADL limitations. For all age

groups, odds for having zero IADL limitations were decreased in people with severe

Covid-19. This effect became however smaller with increasing age. Disease severity, its

interaction with age, and symptoms were associated with a greater number of health

problems. The joint effect of age and degree of severity of Covid-19 on the number of

IADL limitations from both parts of the model is illustrated in Fig 3. In all age groups

having a severe course of Covid-19 was associated with a higher number of self-

reported IADL limitations. Point estimates for survivors with non-severe and those with

severe disease were however closer in the oldest age group. CIs for the number of IADL

limitations in participants with non-severe and those with severe Covid-19 moved closer

in both older age groups and overlapped in survivors aged 61 years and older.

Table 2. Results from zero-inflated Poisson regression of number of IADL limitations on potential risk factors

(n=431)

I. Excess zeros: Prediction of having no IADL limitation	OR (95% CI)	SE	z
Age			

< 50	1 (reference)		
50-60	0.66 (0.24-1.78)	0.51	-0.82
> 60	0.04 (0.01-0.10)	0.54	-6.19
Disease severity and age group			
non-severe and < 50 years old	1 (reference)		
severe and < 50 years old	0.06 (0.02-0.17)	0.51	-5.43
non-severe and 50-60 years old	1 (reference)		
severe and 50-60 years old	0.11 (0.04-0.32)	0.56	-4.02
non-severe and > 60 years old	1 (reference)		
severe and > 60 years old	0.34 (0.10-1.16)	0.62	-1.72
Province			
Other provinces	1 (reference)		
Hubei	0.09 (0.04-0.19)	0.37	-6.46
Ethnicity			
Han	1 (reference)		
Tibetan	0.16 (0.06-0.41)	0.49	3.78
Smoking history			
no	1 (reference)		
yes	1.78 (0.67-4.75)	0.50	1.15
Comorbid conditions			
none	1 (reference)		
one	0.65 (0.29-1.43)	0.41	-1.08
multi	0.33 (0.12-0.90)	0.51	-2.16
II. Count: Number of IADL limitations	IRR (95% CI)	SE	z
Disease severity (reference: non-severe)			
non severe	1 (reference)		
severe	1.64 (0.97-2.80)	0.45	1.84

Disease severity and age group			
non-severe and < 50 years old	1 (reference)		
non-severe and 50-60 years old	1.76 (0.99-3.15)	0.52	1.92
non-severe and > 60 years old	2.91 (1.78-4.77)	0.73	4.24
severe and < 50 years old	1 (reference)		
severe and 50-60 years old	1.34 (1.03-1.74)	0.18	2.21
severe and > 60 years old	1.65 (1.33-2.05)	0.18	4.52
Symptoms, number			
<= 1	1 (reference)		
>1	1.34 (1.10-1.62)	0.13	2.98
Infection scope			
Unilateral	1 (reference)		
Bilateral	1.19 (0.89-1.61)	0.18	1.16

OR = odds ratio, CI = confidence interval, SE = standard error of coefficient, z = standardized coefficient, IRR =

incidence rate ratio, IADL = instrumental activities of daily living.

Fig 3. Effect of the interaction of age and disease severity on the number of

predicted IADL problems (triangles) with 95% confidence intervals (capped lines).

Estimated from zero-inflated Poisson regression. Predictions are adjusted for other

factors in the model. Predictors included in the logistic part (excess zeros) were the

following: age group, interaction of age and disease severity, setting (Hubei vs. other

province), Tibetan ethnicity (reference: Han), smoking history, and comorbid conditions.

Predictors included in the count part were: disease severity, interaction of age and

disease severity, symptoms, and infection scope. The model has been estimated for 431

cases (because of one missing date of birth).

Discussion

This retrospective cohort study found a considerable prevalence of functional limitations and dependence as well as anxiety in Covid-19 survivors at about time of discharge from acute inpatient treatment. Disease severity was a major independent risk factor for all outcomes. Age was an additional risk factor for both disability outcomes, and setting (Hubei) for IADL limitations and anxiety. Tibetan ethnicity was a strong protective factor for anxiety but a risk factor for IADL limitations when it was adjusted for covariates. Demographic and clinical characteristics of the study population were comparable to other reports on Covid-19 patients from China [1, 21] with two exceptions: a higher percentage was classified as severe cases and current smoking was more prevalent in the non-severe disease group. An explanation for the higher percentage of severe cases in the present study is that the applied criteria for classifying Covid-19 cases as severe by the National Health Commission of the PR China are more liberal than the criteria for severe community-acquired pneumonia by the American Thoracic Society and Infectious Disease Society of America[22] used by Guan et al.[21] The lower prevalence of smokers in participants with severe disease was unexpected and contradicts previous evidence in this regard.[21] A possible explanation is that current smoking status was self-reported and participants with more severe disease outcomes did not reveal their true smoking status, perhaps for fear of being stigmatized and held responsible for contracting SARS CoV-2 or the severity of Covid-19.

We found a high prevalence of disability and anxiety, particularly in severe cases. Almost three quarters of severe Covid-19 survivors experienced at least one IADL problem and more than one third had at least moderate ADL dependence. The six

percent of the overall sample with severe ADL dependence are of particular concern

since severe functional dependence has been a reliable predictor of mortality in

populations with other health conditions.[23] No other original study directly investigated

disability outcomes related to Covid-19 so far. Follow up studies of SARS and Middle

East Respiratory Syndrome (MERS) survivors have however shown that decreased

exercise capacity and distance walked, fatigue, sleeping problems, shortness of breath,

reduced self-rated health, work disability, and structural damage (e.g. osteonecrosis)

from corticosteroids were prevalent in survivors even years after onset of symptoms.[11,

24, 25] In addition, access to health care, quality of services, and employment

opportunities of former SARS patients were compromised by enduring stigma[13, 26].

Our findings imply that a large proportion of Covid-19 survivors, particularly those who

experienced severe disease episodes are in need of follow up care and rehabilitation

services. This proportion may be reduced by the integration of early rehabilitation

interventions into acute care[27, 28].

Probable clinical anxiety disorder was found in one third of the overall sample and its

prevalence was almost four-fold increased in severe as compared to non-severe cases.

Previous studies on mental health in the Covid-19 pandemic have been conducted in

the general population[29, 30] and health professionals[31] but not in the patient

population. Studies in SARS survivors have however reported highly elevated long-term

psychiatric morbidity[32] and demonstrated adverse effects on the mental health of

caregivers.[11] Our findings point to the need of psychological counseling during acute

care and mental health follow-up in many Covid-19 survivors to mitigate suffering and

prevent the manifestation of psychiatric disorders.

Major risk factors for mortality due to Covid-19[1, 33] were also major risk factors of

disability: older age and severe disease course both independently increased the

relative risk of IADL limitations and ADL dependence. However, comorbidity[34] had an

adverse effect on disability outcomes in unadjusted analysis only. Though attenuated,

disease severity continued to play a major role when it was adjusted for age, co-

morbidity, and other potential confounders demonstrating an additional effect of Covid-

19 when other known risk factors for disability were held statistically constant. In all age

groups having severe Covid-19 was associated with a higher number of self-reported

IADL limitations. For survivors aged over 60 years we found that the extent of IADL

limitations was more similar in those with non-severe and severe Covid-19 than in the

other age groups. Accordingly, the oldest participants with non-severe Covid-19 were

more similar to survivors with severe disease in the younger age groups. There are two

possible explanations for this phenomenon that deserve further scrutiny: First, older

people have already more activity limitations before they acquire Covid-19. Second, a

non-severe disease course has a greater effect on IADL limitations for them.

Persistence of this effect when it was adjusted for comorbidity speaks for the latter

explanation. Having been treated in hospitals of Hubei province where Covid-19 spread

first and overwhelmed an unprepared health system was furthermore associated with

adverse disability outcomes, particularly IADL limitations. Moreover, belonging to the

Tibetan ethnic minority predicted worse IADL outcomes when it was controlled for other

potential risk factors. Given that the Tibetan population of Sichuan province mainly lives

in rural, mountainous areas, both findings point at the role that environmental factors

including the availability and accessibility of targeted services play in the disablement

process.[35] Our findings indicate that priority in rehabilitation resource allocation should

be given to patients with severe disease course, older people, and those living in

environments with restricted accessibility of services.

Regarding anxiety, outstanding independent risk factors were severity of Covid-19 and

setting, i.e. having been hospitalized in Hubei province. Apart from the specific situation

in hospitals in Hubei, insecurity about causes, transmission patterns, and prognosis

when Covid-19 first occurred likely contributed to this finding. Moreover, we found a

trend for longer length of hospital stay being independently associated with increased

relative risk of anxiety. In contrast to disability outcomes, Tibetan ethnicity was a

consistent protective factor in unadjusted as well as adjusted models of anxiety.

Possible explanations are cultural factors including larger families (due to the non

application of China's one child policy to this group) and greater social cohesion and

support. This finding needs further exploration. Our results point towards heightened

need for psychological support in patients who experienced severe disease episodes

and people from areas hardest hit by the Covid-19 pandemic.

Study Limitations

The present study has limitations. First, baseline data for the outcomes analyzed here

were not available. Because of this we cannot rule out that patients had disability or

anxiety before they contracted Covid-19, indeed having disability may have made

people more vulnerable to the disease [36-38]. However, most patients first presented

already with severe symptoms and baseline information collected before admission is

rare in any disease. Baseline information on comorbidity is thus as close as we get to

baseline disability and the effects of disease severity on outcomes remained consistent

when adjusted for baseline comorbidity in our analysis. Second, we may be criticized for

not having employed some kind of control group. An appropriate control group for the

effects and population under investigation is however difficult to define and to establish.

Age and gender matched general population controls are surely not appropriate

because of the lack of hospitalization. Investigating patients who have been hospitalized

for some other disease would not help disentangle the effects of disease and

hospitalization. Quarantined persons suspected for Covid-19 or those treated at home

may make up an interesting comparator but are difficult to access. We believe that our

comparison of patients with severe and non-severe Covid-19 nonetheless provides initial

evidence for the potential impact of the disease and is an important starting point in

investigating this population's rehabilitation needs. Third, outcome data were self-

reported by patients due to the lack of options for objective measurement. Survivors thus

may have under- or overestimated their physical abilities. Patient-reported outcome

measures have however not been used in this population before to the best of our

knowledge, making it difficult to appraise if and to what degree this kind of problem

existed. Fourth, psychiatric confirmation of anxiety in those screened positive was not

possible. Fifth, this study evaluated outcomes at discharge and conclusions about

longer-term prevalence, spontaneous recovery, and chronic manifestations cannot be

drawn at this point and further follow-up of the cohort is therefore indicated.

Recommendations

In spite of these limitations, there are several recommendations that can be derived from

our findings. First, awareness about possible functional and psychological

consequences of Covid-19 needs to be raised in patients, care providers, and health

policy makers[28]. Second, early psychological[39] and pulmonary rehabilitation

interventions including mobilization and exercise[27, 28, 40] which have been

investigated in other health conditions could be effective and important to meet

therapeutic windows; consequently their application (besides pharmacological

treatments) needs to be studied in the population of Covid-19 patients, particularly those

with severe disease. Third, this involves a better integration of primary care and

psychiatric and rehabilitation services which is unfortunately lacking in many lower as

well as higher resourced countries including China.[41] Fourth, systematic community

follow up and two-way referral systems between community health centers and

specialized hospital units, another weak point of many health systems, need to be

strengthened.[41] Fifth, we recommend that future prospective cohort studies in Covid-

19 survivors include functional and psychiatric outcomes.

Conclusion

A significant proportion of Covid-19 survivors had disability and anxiety at discharge

from hospital. Disease severity was the only independent risk factor with consistent

adverse effects on all outcomes. Health systems need to be prepared for an additional

long-term burden due to Covid-19. This includes raising awareness about mental and

physical health problems of survivors, early interventions, strengthening medical follow

up, and increasing physical and psychological rehabilitation capacity.

Author contributions

CH, SZ and JR had full access to all of the data in the study and take responsibility for

the integrity of the data and the accuracy of the data analysis. CH, SZ, QG, LY, QW, YY

and JR designed the study. WX, XC, YH, DZ, YZ, GZ, SW, YW, ZZ, HL, CZ, BZ, JY, MF,

ZN, BC, CD, and HH collected and processed the data. JR, SZ, QG, CH, and YY

interpreted the data. JR performed the statistical analysis and wrote the first draft of the

manuscript. All other authors revised the manuscript for critical content. All authors

reviewed and approved the final submitted version.

Acknowledgment

We thank all the hospital staff members and coordinators under the CSPRM Covid-19

network for their efforts in collecting the information that was used in this study;

Liangjiang Huang (Tongji Hospital, Tongji Medical College, Huazhong University of

Science and Technology), Xu Qin (No.3 People's Hospital of Chengdu), Minqing Li

(Dazhou Central Hospital), Kehui Hu (Suining Central Hospital) ,and Jinling Zhang (West

China Second University Hospital, Sichuan University) for their dedication to data entry

and verification; Prof. Deying Kang (Epidemiologist, West China Hospital, Sichuan

University) and Mrs. Rouyue Fang (Statistician, Industrial and Commercial Bank of

China) for their assistance in initial data extraction and processing; all the patients who

consented to provide their data for analysis and the medical staff members who are at

the frontline caring for patients with Covid-19. We would like to thank Prof. Dr. Gerold

Stucki and Cristiana Baffone for constructive comments on an earlier version of the

manuscript.

Funding

This study was funded by the National Natural Science Foundation (81972146), the

Department of Science and Technology of Sichuan Province (20YYJC3320), China

Postdoctoral Science Foundation (2020M673251), Health Commission of Sichuan

Province (20PJ034), and West China Hospital of Sichuan University (HX-2019-nCoV-

011 to Chengqi He, and 2019HXBH058 to Siyi Zhu). The funders played no role in the

design, conduct, or reporting of this study.

Competing interests

The authors declare that they have no competing interests.

References

1.   Liang W-h, Guan W-j, Li C-c, Li Y-m, Liang H-r, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. European Respiratory Journal. 2020;55(6).

2.   Center for Evidence Based Medicine (CEBM). Global Covid-19 Case Fatality Rates (last updated on June 6 2020) 2020 [cited 2020 Aug 10]. Available from: https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/.

3.   Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020.

4.   Tucci V, Moukaddam N, Meadows J, Shah S, Galwankar SC, Kapur GB. The Forgotten Plague: Psychiatric Manifestations of Ebola, Zika, and Emerging Infectious Diseases. Journal of global infectious diseases. 2017;9(4):151-6. Epub 2018/01/06. doi: 10.4103/jgid.jgid_66_17. PubMed PMID: 29302150; PubMed Central PMCID: PMC5750439.

5.   Griffiths J, Hatch RA, Bishop J, Morgan K, Jenkinson C, Cuthbertson BH, et al. An exploration of social and economic outcome and associated health-related quality of life after critical illness in general intensive care unit survivors: a 12-month follow-up study. Crit Care.

2013;17(3):R100. Epub 2013/05/30. doi: 10.1186/cc12745. PubMed PMID: 23714692; PubMed

Central PMCID: PMC3706775.

6.   Wunderink RG, Waterer G. Advances in the causes and management of community

acquired pneumonia in adults. BMJ. 2017;358:j2471. Epub 2017/07/12. doi: 10.1136/bmj.j2471.

PubMed PMID: 28694251.

7.   Fraser E. Long term respiratory complications of covid-19. British Medical Journal

Publishing Group; 2020.

8.   Gonzalez-Jaramillo N, Low N, Franco OH. The double burden of disease of COVID-19 in

cardiovascular patients: overlapping conditions could lead to overlapping treatments. European

journal of epidemiology. 2020;35(4):335.

9.   James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and

national incidence, prevalence, and years lived with disability for 354 diseases and injuries for

195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease

Study 2017. The Lancet. 2018;392(10159):1789-858.

10.   Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and

national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life

expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the

Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1859-922.

11.   Tansey CM, Louie M, Loeb M, Gold WL, Muller MP, de Jager J, et al. One-year outcomes

and health care utilization in survivors of severe acute respiratory syndrome. Archives of

internal medicine. 2007;167(12):1312-20.

12.   Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The

psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet.

2020. Epub 2020/03/01. doi: 10.1016/S0140-6736(20)30460-8. PubMed PMID: 32112714.

13.   Siu JY. The SARS-associated stigma of SARS victims in the post-SARS era of Hong Kong.

Qualitative health research. 2008;18(6):729-38. Epub 2008/05/27. doi:

10.1177/1049732308318372. PubMed PMID: 18503014.

14.   National Health Commission of the PR China [国家卫生健康委员会]. Diagnostic criteria

of the Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7) [in

Chinese; 关于印发新型冠状病毒肺炎诊疗方案（试行第七版）的通知] 2020 [cited 2020

March 25]. Available from:

http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.

15.   Tong AY, Man DW. The validation of the Hong Kong Chinese version of the Lawton

Instrumental Activities of Daily Living Scale for institutionalized elderly persons. OTJR:

Occupation, Participation and Health. 2002;22(4):132-42.

16.   Wade DT, Hewer RL. Functional abilities after stroke: measurement, natural history and

prognosis. Journal of neurology, neurosurgery, and psychiatry. 1987;50(2):177-82. Epub

1987/02/01. doi: 10.1136/jnnp.50.2.177. PubMed PMID: 3572432; PubMed Central PMCID:

PMC1031489.

17.   Sze KH, Wong E, Or KH, Lum CM, Woo J. Factors predicting stroke disability at discharge:

a study of 793 Chinese. Archives of physical medicine and rehabilitation. 2000;81(7):876-80.

Epub 2000/07/15. doi: 10.1053/apmr.2000.6279. PubMed PMID: 10895998.

18.   Zung WW. A Rating Instrument For Anxiety Disorders. Psychosomatics. 1971;12(6):371-

9.

19.   Dunstan DA, Scott N. Norms for Zung's Self-rating Anxiety Scale. BMC psychiatry.

2020;20(1):90. Epub 2020/03/01. doi: 10.1186/s12888-019-2427-6. PubMed PMID: 32111187;

PubMed Central PMCID: PMC7048044.

20.   Zou G. A modified poisson regression approach to prospective studies with binary data.

American journal of epidemiology. 2004;159(7):702-6.

21.   Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of

Coronavirus Disease 2019 in China. The New England journal of medicine. 2020. Epub

2020/02/29. doi: 10.1056/NEJMoa2002032. PubMed PMID: 32109013.

22.   Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and

Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice

Guideline of the American Thoracic Society and Infectious Diseases Society of America.

American journal of respiratory and critical care medicine. 2019;200(7):e45-e67. Epub

2019/10/02. doi: 10.1164/rccm.201908-1581ST. PubMed PMID: 31573350; PubMed Central

PMCID: PMC6812437.

23.   Alger HM, Williams Iv JH, Walchok JG, Bolles MM, Fonarow GC, Rutan C. The Role of Data

Registries in the Time of COVID-19. Circulation Cardiovascular quality and outcomes. 2020. Epub

2020/04/17. doi: 10.1161/circoutcomes.120.006766. PubMed PMID: 32298145.

24.   Cao W-C, De Vlas SJ, Richardus JH. The severe acute respiratory syndrome epidemic in

mainland China dissected. Infectious disease reports. 2011;3(1).

25.   Batawi S, Tarazan N, Al-Raddadi R, Al Qasim E, Sindi A, Johni SA, et al. Quality of life

reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health

and quality of life outcomes. 2019;17(1):101.

26.   Lee S, Chan LY, Chau AM, Kwok KP, Kleinman A. The experience of SARS-related stigma

at Amoy Gardens. Soc Sci Med. 2005;61(9):2038-46. Epub 2005/05/26. doi:

10.1016/j.socscimed.2005.04.010. PubMed PMID: 15913861.

27.   Ryrso CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower

mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a

systematic review and meta-analysis. BMC pulmonary medicine. 2018;18(1):154. Epub

2018/09/17. doi: 10.1186/s12890-018-0718-1. PubMed PMID: 30219047; PubMed Central

PMCID: PMC6139159.

28.   Vogiatzis I, Rochester CL, Spruit MA, Troosters T, Clini EM. Increasing implementation

and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement.

The European respiratory journal. 2016;47(5):1336-41. Epub 2016/05/02. doi:

10.1183/13993003.02151-2015. PubMed PMID: 27132269.

29.   Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, et al. RNA based mNGS approach identifies a

novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak.

Emerging Microbes and Infections. 2020;9(1):313-9. PubMed PMID: 2004238813.

30.   Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical

characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive

study. Lancet. 2020;395(10223):507-13. Epub 2020/02/03. doi: 10.1016/s0140-6736(20)30211-

7. PubMed PMID: 32007143; PubMed Central PMCID: PMCPMC7135076.

31.   Lai J, Ma S, Wang Y, Cai Z, Hu J, Wei N, et al. Factors Associated With Mental Health

Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA network

open. 2020;3(3):e203976. Epub 2020/03/24. doi: 10.1001/jamanetworkopen.2020.3976.

PubMed PMID: 32202646; PubMed Central PMCID: PMCPMC7090843.

32.   Mak IWC, Chu CM, Pan PC, Yiu MGC, Chan VL. Long-term psychiatric morbidities among

SARS survivors. General hospital psychiatry. 2009;31(4):318-26.

33.   Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality

of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.

2020;395(10229):1054-62. Epub 2020/03/15. doi: 10.1016/S0140-6736(20)30566-3. PubMed

PMID: 32171076.

34.   Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its

impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. European Respiratory

Journal. 2020;55(5).

35.   WHO. International Classification of Functioning, Disability, and Health. Geneva: WHO

Press; 2001.

36.   Armitage R, Nellums LB. The COVID-19 response must be disability inclusive. The Lancet

Public Health. 2020;5(5):e257.

37.   WHO. Disability considerations during the COVID-19 outbreak: World Health

Organization; 2020 [cited 2020 Aug 10]. Available from:

https://apps.who.int/iris/bitstream/handle/10665/332015/WHO-2019-nCov-Disability-2020.1-

eng.pdf.

38.   Solomon MZ, Wynia MK, Gostin LO. Covid-19 crisis triage—optimizing health outcomes

and disability rights. New England Journal of Medicine. 2020.

39.   Giummarra MJ, Lennox A, Dali G, Costa B, Gabbe BJ. Early psychological interventions for

posttraumatic stress, depression and anxiety after traumatic injury: A systematic review and

meta-analysis. Clinical psychology review. 2018;62:11-36. Epub 2018/05/14. doi:

10.1016/j.cpr.2018.05.001. PubMed PMID: 29754102.

40.   Zhang L, Hu W, Cai Z, Liu J, Wu J, Deng Y, et al. Early mobilization of critically ill patients

in the intensive care unit: A systematic review and meta-analysis. PLoS One.

2019;14(10):e0223185. Epub 2019/10/04. doi: 10.1371/journal.pone.0223185. PubMed PMID:

31581205; PubMed Central PMCID: PMC6776357.

41.   Xiao Y, Zhao K, Ma ZX, Li X, Qiu YP. Integrated medical rehabilitation delivery in China.

Chronic diseases and translational medicine. 2017;3(2):75-81. Epub 2017/10/25. doi:

10.1016/j.cdtm.2017.02.003. PubMed PMID: 29063059; PubMed Central PMCID: PMC5627700.

Supporting information

Table S1. Outcome: One or more IADL problems (Lawton IADL scale, at least one item endorsed)[&]. [&] n= 431 for adjusted model and unadjusted model for age, n= 432 for all other models. RR = Risk Ratio. CI = Confidence Interval.

Table S2. Outcome: At least moderate ADL dependence (Barthel Index, < 75)[&]. [&]n= 431 for adjusted model and unadjusted model for age, n= 432 for all other models. RR = Risk Ratio. CI = Confidence Interval.

Table S3. Outcome: Anxiety (Zung's self-reported anxiety scale, raw score < 40)[&]. [&]n=407 for adjusted model and n=407 for unadjusted model for length of stay, n= 431 for unadjusted model for age, n= 432 for all other models. RR = Risk Ratio. CI = Confidence Interval.

1. Presence of IADL limitations (at least one)

Gender
- female
- male

Age, years
- < 50
- 50-60
- > 60

Province
- other province
- Hubei

Ethnicity
- Han
- Tibetan

Current smoking
- no
- yes

Comorbid condition
- none
- one
- multi

Disease severity
- non-severe
- severe

Symptoms, number
- <= 1
- >1

Infection scope
- unilateral
- bilateral

Model
- unadjusted
- adjusted

Risk ratio and 95% CIs

2. ADL dependence (at least moderate)

Gender
- female
- male

Age, years
- < 50
- 50-60
- > 60

Province
- other province
- Hubei

Ethnicity
- Han
- Tibetan

Current smoking
- no
- yes

Comorbid condition
- none
- one
- multi

Disease severity
- non-severe
- severe

Symptoms, number
- <= 1
- >1

Infection scope
- unilateral
- bilateral

Model
- unadjusted
- adjusted

Risk ratio and 95% CIs